We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+15.92%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$384M
AUM Growth
+$106M
Cap. Flow
+$85.6M
Cap. Flow %
22.32%
Top 10 Hldgs %
38.06%
Holding
80
New
28
Increased
20
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$13.1M
2
CVS icon
CVS Health
CVS
+$12.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$10.6M
4
IVC
Invacare Corporation
IVC
+$10.3M
5
KIDS icon
OrthoPediatrics
KIDS
+$9.75M

Top Sells

Rank Stock Value
1
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$39.1M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$13.1M
3
SIBN icon
SI-BONE Inc
SIBN
+$7.62M
4
SNN icon
Smith & Nephew
SNN
+$7.55M
5
CI icon
Cigna
CI
+$5.22M

Sector Composition

Rank Sector Weight
1 Healthcare 85.83%
2 Industrials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KIDS icon
1
OrthoPediatrics
KIDS
$519M
$19.3M 5.04%
396,162
+203,154
+105% +$9.75M
ATNM icon
2
CALL
Actinium Pharmaceuticals
ATNM
$26.3M
$15.2M 3.97%
+2,000,000
New +$17M
BMY icon
3
Bristol-Myers Squibb
BMY
$133B
$14.8M 3.85%
233,898
-10,168
-4% -$633K
AHCO icon
4
AdaptHealth
AHCO
$1.47B
$14.7M 3.83%
399,730
+249,316
+166% +$8.81M
SNY icon
5
Sanofi
SNY
$103B
$13.5M 3.51%
+272,218
New +$13.1M
BDX icon
6
Becton Dickinson
BDX
$45.6B
$13.2M 3.45%
55,714
-15,282
-22% -$3.73M
CVS icon
7
CVS Health
CVS
$133B
$12.6M 3.28%
+167,362
New +$12.2M
AZN icon
8
AstraZeneca
AZN
$263B
$11.8M 3.09%
119,050
+90,604
+319% +$9.11M
LH icon
9
Labcorp
LH
$25B
$11.5M 3.01%
52,641
+29,554
+128% +$5.93M
ACRS icon
10
Aclaris Therapeutics
ACRS
$726M
$11.5M 2.99%
455,385
-671,290
-60% -$13.1M
ELV icon
11
Elevance Health
ELV
$81.5B
$11.4M 2.98%
31,798
+9,164
+40% +$2.95M
EHC icon
12
Encompass Health
EHC
$11B
$11M 2.86%
168,188
+76,296
+83% +$4.98M
IOVA icon
13
Iovance Biotherapeutics
IOVA
$1.82B
$9.84M 2.56%
310,649
+256,428
+473% +$10.6M
ABBV icon
14
AbbVie
ABBV
$443B
$9.52M 2.48%
87,982
+3,438
+4% +$368K
MTEM
15
DELISTED
Molecular Templates, Inc.
MTEM
$8.95M 2.33%
47,291
+1,875
+4% +$329K
IVC
16
DELISTED
Invacare Corporation
IVC
$8.88M 2.32%
+1,107,112
New +$10.3M
MCK icon
17
McKesson
MCK
$100B
$8.61M 2.24%
+44,132
New +$8.06M
BIO icon
18
Bio-Rad Laboratories Class A
BIO
$8.71B
$8.44M 2.2%
+14,784
New +$8.75M
ELUT icon
19
Elutia
ELUT
$37.9M
$8.06M 2.1%
583,600
+175,387
+43% +$2.62M
SYNH
20
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$8M 2.09%
105,521
+3,568
+3% +$269K
PHAS
21
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$7.49M 1.95%
+2,163,518
New +$8.78M
COR icon
22
Cencora
COR
$60.6B
$7.41M 1.93%
62,722
-15,617
-20% -$1.69M
OCUL icon
23
Ocular Therapeutix
OCUL
$1.79B
$7.2M 1.88%
438,933
+148,468
+51% +$2.86M
AVTR icon
24
Avantor
AVTR
$9.32B
$6.97M 1.82%
241,016
+46,239
+24% +$1.33M
BSX icon
25
Boston Scientific
BSX
$69.5B
$6.13M 1.6%
+158,702
New +$6.01M
1
2 3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Endurant Capital Management held 80 positions worth $384M, up 38% from $277M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Endurant Capital Management deployed $85.6M of net new capital in Q1 2021, opening 28 new positions and adding to 20 existing holdings. Its largest new stake was Sanofi: 272,218 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $13.1M trimmed.

  • Endurant Capital Management's largest Q1 2021 buy was Sanofi: 272,218 shares worth $13.5M.
  • Endurant Capital Management added most to Iovance Biotherapeutics in Q1 2021, an estimated $10.6M increase.
  • Endurant Capital Management's biggest Q1 2021 reduction was Aclaris Therapeutics, cutting an estimated $13.1M.
  • Endurant Capital Management fully exited Oxford Immunotec Global PLC Ordinary Shares in Q1 2021, selling an estimated $39.1M.
  • Endurant Capital Management's ten largest holdings make up 38% of its $384M portfolio in Q1 2021.
  • Endurant Capital Management opened 28 new positions and closed 19 in Q1 2021.
  • Endurant Capital Management's portfolio value rose 38% quarter-over-quarter to $384M.

Based on Endurant Capital Management's 13F filing for Q1 2021, filed 17 May 2021.